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OBJECTIVES The Troponin in Planned PTCA/Stent Implantation With or Without Administration of
the Glycoprotein IIb/IIIa Receptor Antagonist Tirofiban (TOPSTAR) trial investigated: 1)
the amount of troponin T (TnT) release after nonacute, elective percutaneous coronary
intervention (PCI) in patients pretreated with aspirin and clopidogrel; and 2) the effect of
additional glycoprotein (GP) IIb/IIIa receptor inhibiton on postinterventional TnT release.
BACKGROUND No data are available yet as to whether additional administration of a GP IIb/IIIa receptor
antagonist might be beneficial in patients undergoing elective PCI already pretreated with
aspirin and clopidogrel.
METHODS After bolus application of the study medication (tirofiban [T] or placebo [P]), PCI was
performed followed by an 18-h continuous infusion of T/P. Primary end point of the study
was incidence and amount of TnT release after elective PCI after 24 h.
RESULTS A total of 12 h after PCI troponin release was detected in 63% of the patients receiving P and
in 40% of the patients receiving T (p  0.05), after 24 h in 69% (P) and 48% (T) (p  0.05)
and after 48 h in 74% (P) versus 58% (T) (p  0.08) of the patients. No differences were
observed regarding major bleeding, intracranial bleeding or nonhemorrhagic strokes. After
nine months a reduction of combined death/myocardial infarction/target vessel revascular-
ization could be observed in the tirofiban group ([T] 2.3% vs. [P] 13.04%, p  0.05).
CONCLUSIONS Troponin T release occurs after successful intervention in 74% of the patients undergoing
elective PCI after 48 h even after pretreatment with aspirin and clopidogrel. The GP IIb/IIIa
receptor antagonist tirofiban is able to decrease the incidence of troponin release significantly
in this patient population. (J Am Coll Cardiol 2002;40:662–8) © 2002 by the American
College of Cardiology Foundation
Optimal pretreatment in elective percutaneous coronary
interventions (PCI) was mainly based on the administration
of aspirin before or during PCI. After intervention and stent
placement, inhibition of platelet function with the combi-
nation therapy of aspirin with clopidogrel was able to reduce
the incidence of in-stent thrombosis and, furthermore,
mortality in patients with unstable angina (1–3). However,
the impact of pretreatment with this combination therapy in
patients undergoing nonacute PCI on peri- and postproce-
dural troponin release has not yet been analyzed, although
release of creatine kinase (CK) or troponin influences
clinical outcome (4,5). Further inhibition of platelet activity
is achievable by using glycoprotein (GP) IIb/IIIa receptor
antagonists, which are very effective in interventional ther-
apy of acute coronary syndromes (6–10). Some reports
point out that troponin release may occur even in nonacute
PCI procedures (11,12). There was coincidence between
release of cardiac markers and impaired clinical short- and
long-term outcome in those patients (13,14). This study
was, therefore, designed to: 1) determine the time course
and frequency of troponin release as a marker of myocardial
ischemia in nonacute interventions after pretreatment with
the combination therapy of aspirin and clopidogrel, and 2)
test the additional impact of the short acting, peri- and
postprocedurally given GP IIb/IIIa receptor antagonist
tirofiban (Aggrastat, Merck Sharp & Dohme B.V., Haar-
lem, Netherlands) on the release of ischemic parameters after
elective, nonacute PCI in a double-blinded, prospective, ran-
domized trial. Primary end point of the trial was the presence
of postinterventional release of troponin T (TnT) after 24 h;
secondary end point was incidence of death, myocardial infarc-
tion (MI) and target vessel revascularization (TVR).
METHODS
Trial design. The Troponin in Planned PTCA/Stent Im-
plantation With or Without Administration of the Glyco-
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protein IIb/IIIa Receptor Antagonist Tirofiban (TOP-
STAR) trial was a single-center, double-blind, randomized,
prospective trial with 109 patients enrolled. All patients (age
18 and81 years) had a history of stable angina and were
treated by conventional PCI, which was performed as a
staged procedure. All patients were pretreated with a load-
ing dose of thienopyridine (clopidogrel, 375 mg) and aspirin
(500 mg) at least one day before PCI (Fig. 1). Study
medication was administered when the guidewire passed the
target stenosis but before first balloon inflation/direct stent
implantation. After bolus administration (10 g/kg), con-
tinuous infusion of the study medication (0.15 g/kg/min)
was started immediately without interruption in accordance
with the Randomized Efficacy Study of Tirofiban for
Outcomes and Restenosis (RESTORE) trial (8). The study
followed the guidelines of the revised declaration of Hel-
sinki (10.10.75) and was accepted and approved by the
Ethics Committee of the University of Wu¨rzburg.
Inclusion and exclusion criteria. All patients had a target
lesion 70% suitable for PCI. Exclusion criteria were acute
coronary syndromes, subacute or acute MI. Myocardial
infarction was defined as significant electrocardiogram
(ECG) changes (ST-segment elevation 2 mm or ST-
segment depression in combination with elevation of isch-
emic parameters such as elevation of CK with an MB
fraction of 10%); existence and elevation of troponin T
twice the upper limit; unstable angina defined as chest pain
at rest within the last seven days; stenosis located in venous
or arterial bypass grafts; renal insufficiency; recent peptic
ulcers or a history of bleeding, thrombocytopenia or throm-
bolytic therapy within the previous 24 h; stroke during the
past two years; severe hypertension; neoplasms; and previous
or planned administration of a GP IIb/IIIa receptor antag-
onist.
Definition of complications. Bleeding was classified as
minor (prolonged bleeding after sheath removal or necessity
of prolonged compression without a drop in hemoglobin
more than 2 g/dl), major (hemoglobin loss of 5 g/dl or
necessity of red blood cell transfusion) and severe (death,
MI or early reintervention within 24 h, the development of
acute coronary syndromes with characteristic temporary
ECG changes, nonhemorrhagic strokes or intracranial
bleeding).
Patient randomization and blood sampling. The patients
were randomized (tirofiban [T] vs. placebo [{P} 0.9% NaCl
solution]) by an independent study nurse. Unfractionated
heparin was given in a dosage of 5,000 U to 10,000 U in
both groups with a target activated clotting time (ACT) of
250 s. Mean heparin dosage during PCI was 8,388  228
IU (T) and 9,089  308 IU (P) (p  NS). Activated
coagulation time was similar in both groups (T: 242 7.9 s,
P: 244  9.1 s) (p  NS). Blood samples for analysis of
white and red blood count, CK/CK-MB, TnT, myoglobin,
partial thromboplastin time and international normalized
ratio were collected before PCI and 30 min (34  2.2 min),
2 h (148 [2 h 28 min]  4.2 min), 6 h (389 [6 h 29 min]
 7.4 min), 12 h (708 [11 h 48 min]  14.4 min), 24 h
(1,482 [24 h 42 min]  20.6 min) and 48 h (3,047 [50 h 47
min]  68.5 min) after the procedure. Thrombocyte inhi-
bition was measured on-line using Ultegra (Accumetrics,
San Diego, California) rapid platelet function assay (RPFA)
before, after bolus administration, 6 h, 12 h, 24 h and 48 h
after PCI (15,16). The results of the level of platelet
inhibition during PCI were analyzed by the study nurse and
not forwarded to the investigating physician. Patients in this
analysis were stated to be troponin-positive when exceeding
the decision limit (99th percentile of the values for a
reference control group) of the laboratory cutoff level of
Abbreviations and Acronyms
ACT  activated clotting time
CK  creatine kinase
GP  glycoprotein
MI  myocardial infarction
P  placebo group
PAU  platelet aggregation units
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
RPFA  rapid platelet function assay
T  tirofiban group
TnT  troponin T
TOPSTAR  Troponin in Elective PTCA/STent
Implantation With or Without
Administration of the Glycoprotein IIb/
IIIa Receptor Antagonist Tirofiban
TVR  target vessel revascularization
Figure 1. Flow-chart of the TOPSTAR trial. After diagnostic catheterization the patients were pretreated with aspirin (ASA) and clopidogrel. After
randomization the patients underwent elective percutaneous coronary intervention (PCI) in a second stage procedure with either peri- and postprocedural
placebo or tirofiban infusion for 18 h. For details see Methods sections.
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0.009 g/ml compared with pre-PCI levels. Troponin T
was measured with TnT STAT immunoassay (ECLIA) of
Roche Elecsys 2010 (Roche Diagnostics GmbH, Mann-
heim, Germany).
Patients. Of 109 patients enrolled, 96 patients could finally
be included in the study. Patients were excluded because of
technical reasons (five patients); in three patients the index
stenosis was due to initial coronary spasm, and PCI was not
performed; one patient was excluded due to wire-induced
side-branch perforation before administration of the study
medication; three patients with lesions primarily suitable for
PCI preferred the option of bypass surgery due to personal
conviction; and one patient had to be unblinded, and study
medication had to be stopped 4 h after PCI due to nonrelevant,
but continuously ongoing, nose bleeding and was counted in
the intention-to-treat analysis as a bleeding patient.
Patients characteristics and baseline medication. Both
groups were similar in baseline characteristics like sex,
weight, size, body mass index, cardiovascular risk factors,
recent MI (defined as MI 14 days before diagnostic
catheterization) and medication at admission (Table 1).
Statistical analysis. For comparing patient characteristics
and troponin release, chi-square test was applied with borders
of 3.84 for a p level of significance with value of 0.05 and
6.63 for p  0.01. For group comparison Mann-Whitney U
test was performed. A level of p  0.05 was considered to
indicate a statistically significant difference.
RESULTS
Angiographic and interventional data. There was a ho-
mogenous, nonsignificant distribution regarding the num-
ber of stents placed, the number of direct stenting or
percutaneous transluminal coronary angioplasty (PTCA)
without stenting, number of dilations, inflation pressure,
location of stenosis, number of side-branch occlusions and
mean diameter of the stents between both groups (Table 2).
Clinical outcome and complications. All patients under-
went successful PCI with a Thrombolysis in Myocardial
Infarction (TIMI) flow grade 3 after the procedure. There
were no ischemic strokes or intracranial bleeding. Transfu-
sion of red blood cells was necessary in one patient in each
group due to femoral bleeding (p  NS). In one patient
infusion was terminated after 4 h for nonsevere, but con-
tinuously ongoing, nose bleeding without significant drop in
hemoglobin. The patient was regarded as an intention-to-
treat patient and was regarded as a minor bleeding patient.
Minor bleeding was more prominent in the T group
(16.0%) than in the P group (8.7%) (p  NS).
Platelet function. All patients were on aspirin and clopi-
dogrel before the PCI procedure. The mean platelet acti-
vation units (PAU) before the intervention was 142.6  5.4
(T) versus 146.3  7.2 (P). After bolus application platelet
function was reduced to PAU 10.8  1.4 (7.8  1.0% of
baseline) in the T group. The aggregation units in the
P group increased up to 171.7  5.6 PAU (128.5  7.9%,
p  0.001 vs. T). During administration of the study drug,
platelet function levels were 9.5  1.2 PAU (7.0  0.9%,
p  0.001 vs. P) at 6 h and 12.3  2.4 PAU (9.8  2.3%,
p  0.001 vs. P) at 12 h in the T group. At 48 h platelet
function levels had normalized to 112.6 5.9 PAU (83.3
4.3%) in the T group and 129.5  6.9 PAU (98.7  6.3%,
p  NS) in the P group (Fig. 2).
Coagulation parameters. Two patients in the T group
developed thrombocytopenia, which was fully reversible
after cessation of the study medication. PTT was similar in
both groups before PCI (T: 30.99  0.55 s; P: 30.47 
0.46 s) increasing during PCI (T: 142.37  3.79 s, P:
147.87  1.47 s, p  NS) and at 2 h after PCI (T: 102.29
Table 1. Baseline Characteristics and Patient Medication
Tirofiban
(n  50)
Placebo
(n  46)
Level of
Significance
Age (yrs) 63.7  1.5 65.5  1.6 NS
Gender (% male) 74.0 76.1 NS
Weight (kg) 79.3  1.8 80.0  1.9 NS
Size (cm) 171.0  1.1 170  0.9 NS
BMI 27.06  0.44 27.68  0.55 NS
Smokers (%) 40.0 34.8 NS
Hypertension (%) 74.0 76.1 NS
Hyperlipoproteinemia (%) 74.0 87.0 NS
Positive family history (%) 61.2 52.2 NS
Diabetes (%) 20.0 26.1 NS
Recent infarction (%) 42.0 34.8 NS
Glycosides (%) 8.0 6.5 NS
Beta-blocker (%) 62.0 47.8 NS
Calcium antagonists (%) 8.0 8.7 NS
ACE inhibitors/
AT antagonists (%)
38.0 41.3 NS
Nitrates (%) 12.0 28.3 NS
Diuretics (%) 32.0 15.2 NS
Lipid lowering agents (%) 50.0 52.2 NS
Aspirin on admission (%) 88.0 84.8 NS
Aspirin prior to PCI (%) 100 100 NS
Clopidogrel prior to PCI (%) 100 100 NS
ACE  angiotensin-converting enzyme; AT  angiotensin receptor; BMI  body
mass index; NS  not significant; PCI  percutaneous coronary intervention.
Table 2. Angiographic and Interventional Data of the
TOPSTAR Trial
Tirofiban
(n  50)
Placebo
(n  46)
Level of
Significance
Stents placed (%) 92 91.3 NS
Direct stenting (%) 32 17.4 NS
Mean diameter of
stents (mm)
3.5  0.2 3.6  0.16 NS
Number of stents placed 1.14  0.08 1.04  0.07 NS
PTCA without stent
implantation (%)
8 8 NS
Stenosis located in RCA (%) 25 22 NS
Stenosis located in LAD (%) 45 46 NS
Stenosis located in LCX (%) 30 32 NS
Number of dilations 1.3  0.2 1.4  0.2 NS
Inflation time (s) 77.2  6.7 85.6  6.9 NS
Inflation pressure (atm) 12.1  0.3 12.1  0.3 NS
Side branch occlusion (%) 2.1 4 NS
LAD  left anterior descending artery; LCX  left circumflex artery; NS  not
significant; PTCA  percutaneous transluminal coronary angioplasty; RCA  right
coronary artery.
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 6.10 s, P: 115.21  6.29 s). At 6 h PTT had returned to
baseline levels (T: 30.70  0.68 s, P: 33.43  1.41 s, p 
NS).
TnT. In both groups there was a continuous increase in
TnT levels up to 48 h. There was a nonsignificant trend at
all time intervals toward lower troponin levels in the T
group. Troponin T increase at 48 h was 0.0291  0.0094
g/l in the T group versus 0.036 0.01 g/l in the P group
referred to preprocedural levels (p  NS). At 12 h 40% of
patients in the T group but 63% in the P group revealed
TnT (0.01 g/l, p  0.05). At 24 h 48% of the T group
and 69% of the P group were TnT positive (p  0.05). At
48 h 58% of the T patients and 74% of the P patients
revealed a positive TnT (p  NS) (Fig. 3). The number of
a biphasic postinterventional troponin elevations were sig-
nificantly higher in the P group (24%) than in the T group
(8%, p  0.05).
CK/CK-MB fraction. Creatine kinase before PCI was
37.9  5.2 U/l in the T group and 36.4  2.4 U/l in the P
group (pNS). There were no significant differences in the
time course of CK or serum-CK/MB fraction between both
groups with a peak at 48 h (CK: T, 55.6  9.0 U/l; P, 49.6
 5.6 U/l; p  NS)
Death/MI/urgent vessel revascularization. After 30 days
one patient of the P group was readmitted to the hospital
due to stent occlusion and consecutive MI, and no event was
Figure 2. Platelet function before and after percutaneous coronary intervention. During tirofiban infusion platelet function was inhibited down to 10% of
the initial value. Platelet activation was observed in the placebo group. Solid bar  tirofiban (n  50); open bar  placebo (n  46). ***p  0.001; *p 
0.05. Data  SEM.
Figure 3. Percentage of patients with positive troponin after successful percutaneous coronary intervention up to 12 h, 24 h and 48 h. Solid bar  tirofiban
(n  50); open bar  placebo (n  46). *p  0.05.
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regarded in the T group. After nine months one patient of
the T group (2.3%) and five patients of the P group were
readmitted because of MI or need for bypass surgery; one
additional patient died (13.04%; p  0.05; Fig. 4).
DISCUSSION
The TOPSTAR trial focused on: 1) the impact of troponin
release in elective, nonacute PCI solely in patients pre-
treated with aspirin and clopidogrel before PCI; and 2) the
additional effect of temporary, peri- and postprocedural GP
IIb/IIIa receptor inhibition due to administration of the GP
IIb/IIIa receptor antagonist tirofiban. Even after pretreat-
ment with aspirin and clopidogrel, up to 74% of the patients
in the TOPSTAR trial were positive for TnT after 48 h in
elective, nonacute PCI indicating the presence of myone-
crosis. Administration of the GP IIb/IIIa receptor antago-
nist tirofiban before and up to 18 h after PCI was able to
significantly decrease the number of TnT-positive patients
up to 24 h. After nine months a significant reduction of the
combined secondary end point death/MI/TVR could be
observed in the T group.
Pretreatment with aspirin and clopidogrel. Platelet inhi-
bition with aspirin and clopidogrel is cumulatively effective
and significantly reduces subacute stent thrombosis and
mortality in acute coronary syndromes (1–3). In the TOP-
STAR trial, all patients were pretreated with a combination
of aspirin and clopidogrel. The reduced amount of myone-
crosis, as demonstrated by the lack of TnT release is,
therefore, a beneficial effect of GP IIb/IIIa antagonism,
which occurs on top of the pretreatment therapy and
platelet inhibition level with aspirin and clopidogrel.
Platelet inhibition with aspirin, clopidogrel and tirofiban.
The (AU-Assessing Ultegra) Multicenter Study (GOLD)
trial (16) could demonstrate a clear correlation between the
level of platelet inhibition, as measured with the Ultegra
RPFA assay (15–17), and major adverse cardiac events. The
authors concluded that a level of at least 90% inhibition is
necessary to reduce events in PCI. Besides a possible
confoundation of the Global Utilization of Streptokinase
and t-PA for Occluded Coronary Arteries (GUSTO) IV
study by patients without unstable angina but with positive
troponin (e.g., patients with heart failure), another reason
contributing to the negative outcome (18) might partly be
related to an inhomogenous level of inhibition of the
platelets over the time of administration with the GP
IIb/IIIa inhibitor abciximab as demonstrated by Chew and
Molitero (19). This effect has not been observed with the
small molecules eptifibatide or tirofiban (17). In the TOP-
STAR trial, tirofiban was chosen as GP IIb/IIIa antagonist
because of its temporary efficacy to allow the observation of
postinhibitional effects up to 48 h. The levels of inhibition
measured with the Ultegra RPFA system were over 90% at
the time intervals after bolus application and after 6 h and
12 h infusion of tirofiban (Fig. 2) and was referred to an
already reduced baseline level due to the administration of
the fixed combination of aspirin and clopidogrel before PCI.
The activation of platelets by unfractionated heparin, as
observed in the P group, is a well-known phenomenon (20).
Correlation between troponin/CK-MB and outcome.
Release of CK-MB mass or TnT or TnI is a strong
indicator of myocardial damage (21,22). However, to detect
minor myocardial injury, cardiac TnT has been shown to be
superior to CK and its MB fraction (23,24). Furthermore,
the amount of TnT or I or MB mass of CK release is
Figure 4. Combined end point of death/myocardial infarction (MI)/target vessel revascularization (TVR) after 30 days and nine months indicating a
significant reduction in the tirofiban-treated group after nine months.
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correlated with the amount of necrotic myocardial cells and
infarct size. In a meta-analysis of the C7E3 AntiPlatelet
Therapy in Unstable Refractory Angina (CAPTURE),
Evaluation of c7E3 for Prevention of Ischemic Complica-
tions (EPIC) and Evaluation in PTCA to Improve Long-
term Outcome with abciximab Glycoprotein IIa/IIIb
Blockade (EPILOG) trials (25), a correlation between
modest elevation of cardiac enzyme and an impaired late
outcome was found. Mild to moderate periprocedural ele-
vation of CK-MB is related to an increased subsequent MI
and mortality (26). Even small CK elevation after elective
PTCA was associated with increased late cardiac mortality
(27). It was demonstrated that CK-MB (5%) can be
increased in up to 26% of patients after “uncomplicated”
coronary interventions (28,29). Regarding the recently pub-
lished redefinition of MI by the Joint Commission of the
European Society of Cardiology/American College of Car-
diology Committee, even modest elevation of cardiac pa-
rameters have to be classified as an MI (30). However, the
reduced secondary end point death/MI/TVR in the T group
after nine months further supports these observations.
Role of microembolization and temporary vessel occlu-
sion during PCI. The increase of ischemic parameters
after PCI might partially be related to inflation-induced
temporary vessel occlusion during PCI (31). However, this
might contribute to the high baseline values of troponin-
positive patients after 12 h but is unlikely to be responsible
for the significant differences between the two treatment
groups, as all interventional parameters were the same in
both groups (Table 2). Mechanical manipulation during
PTCA or stent implantation can lead to embolization of
debris or calcified plaque material or exposure of thrombo-
geneous material at intravascular sites. Furthermore, PCI
procedures activate the expression of GP IIb/IIIa receptor
on the platelet surface (32) and may lead to formation of
microthrombi. The debris can embolize or impede the
microcirculation by secondary thrombus formation and was
reported in patients with acute coronary syndromes or
degenerated saphenous vein grafts (33) but was believed to
be uncommon in routine PCI procedures (34,35). Surpris-
ingly, 74% in the P group of the TOPSTAR trial developed
positive troponin within the first 48 h after PCI. This might
explain the impaired coronary flow reserve, which has been
described by Hermann (36), after elective coronary stenting.
The significant reduction of troponin release by 23% within
12 h and 21% within 24 h after PCI in those patients
receiving tirofiban leads to three conclusions: 1) microem-
bolization during coronary interventions can be reduced by
administration of the GP IIb/IIIa receptor antagonist tiro-
fiban; 2) a large amount of microembolization may be either
refractory to GP IIb/IIIa inhibition, as shown by 40% of
patients being troponin-positive, even after successful and
effective inhibition of platelet aggregation, or may be due to
temporary PCI-induced vessel occlusion; and 3) after ces-
sation of antiaggregational therapy, 10% of the patients in
the T group became troponin-positive between 24 h and
48 h, indicating late microembolization after cessation of
aggressive platelet inhibition. After 48 h the difference
between both groups lost statistical significance, which
might be due to the relative small number of patients in the
two arms of the study, due to late platelet aggregation after
cessation of “aggressive” antiplatelet therapy or a “rebound
phenomenon” in terms of platelet GP IIb/IIIa receptor
activation. Unlike the expected drop of troponin after 24 h,
TnT levels further increased up to 48 h, indicating pro-
longed impairment of myocardial perfusion. A possible
explanation could be a continuous, ongoing, stent-derived
microembolization leading to repetitive release of microem-
boli with obstruction of microvessels.
Study limitations. Administration of tirofiban was started
shortly before the PCI procedure. Administration starting
earlier or longer might have further improved the results
obtained by GP IIb/IIIa receptor-inhibition. Regarding the
results of Treat Angina with Aggrastat and determine Cost
of Therapy with an Invasive or Conservative Strategy
(TACTICS)-TIMI 18, an ACT of 250 s in combination
with tirofiban might be associated with poorer clinical
outcome in the respective patient population (7). However,
the TOPSTAR trial was designed and finished before the
data were available; a higher peri-interventional ACT might
have improved the results. The high incidence of positive
TnT patients might be the result of a low cutoff point in
measuring troponin levels. According to the recommenda-
tions of the Joint Commission of the European Society of
Cardiology and American College of Cardiology, patients
were considered troponin-positive when reaching a cutoff in
the laboratory test of 0.01 g/l and were stated to be
troponin-positive when troponin exceeded the cutoff point
only once during the time interval after PCI up to 48 h.
However, these multiple measurements performed in the
TOPSTAR trial demonstrated the importance of various
time intervals in order to estimate the time course of
ischemic events after percutaneous intervention.
Clopidogrel pretreatment was performed with 375 mg at
least one day before PCI. Higher dosages of clopidogrel
might have decreased the amount of troponin release by
stronger baseline inhibition of platelet function in both
groups. The follow-up of this study included nine months
postinterventional data. However, compared with the En-
hanced Suppression of Platelet Receptor IIb/IIIa using
Integrilin Therapy (ESPRIT) trial (37), the rate of mortal-
ity and TVR was 13.04% in the P group versus 2.3% in the
T group for up to nine months, which underlines the
low-risk patient collective of the study and might, further-
more, be a result of the combination pretreatment of aspirin
and clopidogrel before PCI.
Conclusions. Additional temporary peri- and postproce-
dural administration of the GP IIb/IIIa receptor antagonist
tirofiban leads to a reduced incidence of postinterventional
troponin release in elective, nonacute PCI in patients
pretreated with aspirin and clopidogrel. Larger studies are
warranted to evaluate the benefits of this therapeutic regi-
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men in terms of long-term mortality, MI, rehospitalization,
myocardial salvage and economic aspects in this “low-risk”
patient population, representing the vast majority of pa-
tients undergoing PCI.
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